AzurRx BioPharma, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2020. The filing identifies the registrant as AzurRx BioPharma, Inc., not Gridai Technologies Corp.; verify the company identity associated with this request.
Business context
AzurRx is a clinical-stage biotechnology company developing non-systemic treatments for gastrointestinal disorders, led by MS1819 for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. It reported no product revenue. The filing describes two Phase 2 studies: the OPTION 2 monotherapy trial and a European combination-therapy trial.
Financial performance and position
| Metric | Q3 2020 / September 30, 2020 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None | None in Q3 2019 |
| Operating expenses | R&D $1.80 million; G&A $1.92 million | Q3 2019: R&D $2.22 million; G&A $1.86 million |
| Operating loss | $3.71 million | Q3 2019: $4.08 million |
| Net loss | $5.31 million; $0.47 per common share | Q3 2019: $4.19 million; $0.17 per share |
| Nine-month net loss | $15.27 million; $0.84 per share | Nine months 2019: $13.90 million; $0.66 per share |
| Cash and current liquidity | Cash $11.37 million; current assets $11.54 million; current liabilities $2.63 million | December 31, 2019 cash $0.18 million; current assets $3.41 million; current liabilities $4.29 million |
| Operating cash flow | Nine-month cash used: $5.33 million | Nine months 2019: $10.81 million used |
| Debt and equity | No convertible debt or note payable outstanding; total liabilities $2.66 million; stockholders’ equity $14.07 million | December 31, 2019 convertible debt $1.08 million and note payable $0.44 million |
No meaningful gross margin or operating margin is reported because the company had no revenue. The nine-month cash outflow improved year over year, while net loss increased, largely reflecting noncash debt-discount accretion and other financing-related charges.
Material changes and financing
- In July, the company completed a Series B preferred-stock and warrant financing, receiving approximately $15.2 million gross and $13.2 million net cash proceeds. It also exchanged approximately $7.2 million of notes and accrued interest for preferred stock and warrants; after repaying nonparticipating holders, no convertible notes remained outstanding.
- The Series B carries a 9% cumulative dividend and a liquidation preference; the filing reports an aggregate liquidation preference of approximately $22.6 million at September 30. The preferred shares were initially convertible into approximately 29.1 million common shares, alongside substantial warrant issuance.
- Net loss applicable to common stockholders included an $8.16 million deemed preferred-stock dividend. This increased common-stockholder loss for EPS purposes but was not a cash operating expense.
- Common shares outstanding were 28.88 million at September 30 and 30.41 million as of November 13. The filing also reports 25.20 million warrants outstanding at September 30, in addition to preferred-stock conversion and option dilution potential.
- At September 30, the company had approximately $14.0 million of unused availability under its $15 million Lincoln Park equity line, subject to its terms.
Outlook, risks, and unusual items
- Clinical outlook: The company anticipated OPTION 2 topline data in Q1 2021 and combination-trial topline data in the first half of 2021; both timelines could be delayed by COVID-19. The OPTION 2 trial began dosing in August 2020. The company reported positive interim results for the first five combination-trial patients, including the primary efficacy endpoint and no serious adverse events; these preliminary results are not final trial evidence.
- Spending outlook: Management expected R&D spending to increase as both trials and manufacturing-related activities advanced. It also expected G&A spending to increase, including legal, investor-relations, business-development, and information-security costs. No revenue or profitability guidance was provided.
- Going concern: The filing states that recurring losses, negative operating cash flow, and dependence on external financing raise substantial doubt about the company’s ability to continue as a going concern. It warns that COVID-19 could impair future fundraising.
- Nasdaq: The company had received a minimum-bid-price deficiency notice and a separate stockholders’ equity deficiency notice. It reported September 30 equity of $14.07 million, above the $2.5 million minimum, and expected to resolve the equity matter after filing. The bid-price deficiency remained a risk, with a stated compliance deadline of December 3, 2020.
- Unusual financing costs: Nine-month interest expense was $5.84 million, driven largely by amortization of debt discounts on convertible notes; the note exchange also generated a $0.61 million extinguishment loss. A former-CEO settlement generated a $0.21 million gain.
- Management reported disclosure controls were effective and no material change in internal control over financial reporting. The filing listed no legal proceedings or material changes to previously disclosed risk factors.
Key facts for investors to verify
- Confirm the registrant’s identity: the supplied metadata says Gridai Technologies Corp., while the filing is for AzurRx BioPharma, Inc.
- Check subsequent filings for actual trial enrollment, final clinical results, regulatory developments, and any COVID-related delays.
- Review cash use and financing needs against the going-concern warning; the September cash balance reflects financing proceeds, not operating profitability.
- Assess the full dilution and senior claims from Series B conversion rights, cumulative dividends, liquidation preference, warrants, equity-line issuance, and stock-based awards.
- Confirm the eventual resolution of Nasdaq’s bid-price and stockholders’ equity listing matters.
- Review the preferred-stock terms, financing costs, and any subsequent equity or debt issuances for changes to liquidity and ownership.